Difference between revisions of "Talk:Assessment of the health impacts of H1N1 vaccination"
From Testiwiki
m |
m |
||
| Line 17: | Line 17: | ||
* [[Talk:Assessment of the health impacts of H1N1 vaccination/Group D]] | * [[Talk:Assessment of the health impacts of H1N1 vaccination/Group D]] | ||
* [[Talk:Assessment of the health impacts of H1N1 vaccination/Group E]] | * [[Talk:Assessment of the health impacts of H1N1 vaccination/Group E]] | ||
| + | |||
| + | |||
| + | '''Additional material: | ||
| + | * [[:File:Swine flu story.ppt]] | ||
| + | * [[Decision analysis and risk management#See also]] | ||
Revision as of 21:11, 31 March 2011
Pandemrix should not be used because of narcolepsy risk
| Statements: Pandemrix should not be used any more anywhere because its narcolepsy risk is too high.
Resolution: Resolution not yet found. (A stable resolution, when found, should be updated to the main page.) |
| Argumentation:
⇤1 : Despite risks, Pandemrix is an effective vaccine and has clearly net positive effects in countries where emergency treatment is poorly available for severe swine flu cases. --Jouni 23:05, 31 March 2011 (EEST) ←2 : The reputation of Pandemrix is globally so poor that it is impossible to use it any more. --Jouni 23:05, 31 March 2011 (EEST) |
Discussion groups:
- Talk:Assessment of the health impacts of H1N1 vaccination/Group A
- Talk:Assessment of the health impacts of H1N1 vaccination/Group B
- Talk:Assessment of the health impacts of H1N1 vaccination/Group C
- Talk:Assessment of the health impacts of H1N1 vaccination/Group D
- Talk:Assessment of the health impacts of H1N1 vaccination/Group E
Additional material:
